Key result
Antithrombotic therapy after complex PCI must prioritize bleeding risk over procedural complexity, with P2Y12 inhibitor monotherapy after 1-3 months of DAPT reducing major bleeding without increasing ischemic events.
Why the study?
Patients undergoing complex PCI frequently carry high bleeding risk alongside high ischemic risk, making the selection of antithrombotic regimens challenging as guidelines emphasize balancing both risks.
What are the optimal antithrombotic strategies to balance ischemic and bleeding risks in patients undergoing complex percutaneous coronary intervention?
What are the optimal antithrombotic strategies to balance ischemic and bleeding risks in patients undergoing complex percutaneous coronary intervention?
This comprehensive review highlights that bleeding risk should be prioritized over procedural complexity when selecting antithrombotic duration and intensity after complex PCI, supporting P2Y12 inhibitor monotherapy after short DAPT in high bleeding risk patients and prolonged DAPT only in non-high bleeding risk patients.
Answers are grounded in this paper and cite their sources.
Supports bleeding-focused antithrombotic selection after complex PCI; extends consensus yet leaves open dedicated randomized confirmation.
Complex percutaneous coronary intervention (PCI) represents a growing proportion of contemporary coronary revascularization, driven by aging populations, increasing comorbidity burden, and advances in interventional techniques. Complex PCI encompasses a spectrum of anatomically and procedurally challenging lesions, including left main disease, bifurcation lesions requiring two-stent strategies, chronic total occlusions, long stent lengths, severe calcification requiring atherectomy, and multivessel revascularization. Antithrombotic therapy, comprising antiplatelet and anticoagulant agents, is essential for preventing stent thrombosis and other ischemic events in both the early and long-term phases after PCI. While antithrombotic therapy mitigates ischemic risks associated with complex PCI, these patients frequently carry a high bleeding risk, thus making the choice of antithrombotic regimen challenging. Recent guideline recommendations emphasize balancing ischemic and bleeding risks rather than relying solely on procedural complexity. This review synthesizes contemporary evidence, guideline recommendations, and clinical considerations for antithrombotic therapy after complex PCI.
No takes yet. Share an insight, caveat, or question.
Ueki et al. (2026) conducted a review in Complex percutaneous coronary intervention (PCI). Tailored antithrombotic strategies (P2Y12 inhibitor monotherapy after 1-3 months of DAPT, prolonged DAPT, de-escalation, or dual pathway inhibition) vs. Standard 12-month dual antiplatelet therapy (DAPT) or triple antithrombotic therapy was evaluated. Antithrombotic therapy after complex PCI must prioritize bleeding risk over procedural complexity, with P2Y12 inhibitor monotherapy after 1-3 months of DAPT reducing major bleeding without increasing ischemic events.
Synapse has enriched 10 related papers. Consider them for comparative context: